Covid-19 roundup: Vaccines will need to beat placebo by 50% to qualify for FDA OK; UK trial drops Kaletra
The FDA will set the bar for approving a Covid-19 vaccine at 50% efficacy, the Wall Street Journal reported, meaning any successful candidate will have to reduce the risk of coronavirus disease by at least half compared to placebo.
That requirement is part of guidance that the agency is set to release later today, laying out detailed criteria for vaccine developers — some of whom are eyeing an OK by the end of the year, in line with expectations at Operation Warp Speed.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.